分化型甲状腺癌生存:AJCC第7版与第8版分期系统比较
该研究回顾性分析了2579例在MD Anderson癌症中心接受手术的分化型甲状腺癌患者,比较AJCC第7版与第8版分期系统的生存预测能力。第8版导致I期和II期患者比例增加,III期和IV期比例减少,两版在疾病特异性生存预测上相似(C-index均为0.94),但第8版中<55岁II期患者生存显著差于≥55岁II期患者。
要点
- 第8版分期使I期和II期患者比例分别从62%和5%增至83%和12%。
- 两版C-index均为0.94,疾病特异性生存预测能力相似。
- 第8版中<55岁II期患者DSS显著差于≥55岁II期,但与≥55岁III/IV期相似。
核心结论
- AJCC第8版与第7版在分化型甲状腺癌疾病特异性生存预测上相似(C-index均为0.94)。
- 未来版本可考虑重新评估T3b肿瘤类别及将<55岁伴远处转移患者上调分期。
研究设计与样本
- 回顾性研究,纳入2000至2015年在MD Anderson癌症中心接受手术的2579例分化型甲状腺癌患者。
- 采用Kaplan-Meier法估计生存,log rank检验比较,Cox比例风险模型评估预测因素。
主要发现
- 第8版使I期和II期患者比例分别从62%和5%增至83%和12%,III期和IV期分别从20%和14%降至2%和3%。
- 第7版I-IV期10年DSS分别为100%、97.5%、98.3%、82.6%;第8版对应分期分别为99.8%、88.3%、72.4%、71.9%。
- 多因素分析中,两版均显示年龄较大、肿瘤大小分期进展和远处转移预测更差DSS,颈部淋巴结转移不预测更差生存。
- 第8版中<55岁II期患者DSS显著差于≥55岁II期患者(p<0.001),但与≥55岁III期(p=0.742)和IV期(p=0.566)相似。
- ≥55岁T3a和T3b患者10年DSS分别为67%和92%(p=0.390)。
关键数值与推荐
- 第7版C-index 0.94,PVE 4.6%;第8版C-index 0.94,PVE 4.8%。
- 第8版中<55岁II期患者与≥55岁III期比较p=0.742,与IV期比较p=0.566。
- ≥55岁T3a与T3b的10年DSS比较p=0.390。
临床怎么用
- 临床可采用AJCC第8版分期进行分化型甲状腺癌生存预测,其预测能力与第7版相似。
- 对<55岁II期患者应关注其较差生存,可能需更积极管理。
- T3b类别及<55岁伴远处转移患者的分期分配需进一步研究优化。
局限性
- 单中心回顾性研究,可能存在选择偏倚。
- 样本来自MD Anderson癌症中心,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The American Joint Committee on Cancer Cancer Staging System for differentiated thyroid cancer has been recently revised. The purpose of this study was to compare survival prognostication between the seventh and eighth editions. MATERIALS AND METHODS: We retrospectively reviewed 2579 differentiated thyroid cancer patients who underwent surgery at MD Anderson Cancer Center between 2000 and 2015. Disease-specific survival (DSS) and overall survival were estimated using the Kaplan-Meier method and compared using log rank test. The effect of potential predictor was estimated using Cox proportional hazards model. Power of survival prediction was estimated using Harrell's C concordance index (C-index), and predictive capacities for DSS were estimated using proportion of variance explained (PVE). RESULTS: Revision of tumor-node-metastasis (TNM) categories, age cutoff, and stage reassignment in the 8th edition caused reclassification of overall stage compared with the seventh edition. The proportion of patients in stage I and II increased from 62% to 83% and 5% to 12%, respectively, while the proportion of patients in stage III and IV decreased from 20% to 2% and 14% to 3%, respectively. Ten-year DSS for stages I-IV based on the seventh edition were 100%, 97.5%, 98.3%, and 82.6%, respectively, while 10-year DSS for the corresponding stage in the eighth edition were 99.8%, 88.3%, 72.4%, and 71.9%, respectively. In multivariate analysis for both seventh edition (C-index 0.94, PVE 4.6%) and eighth edition (C-index 0.94, PVE 4.8%), the factors predictive of worse outcome for DSS were older age, advanced tumor size category, and distant metastasis while cervical lymph node metastases did not predict worse survival. For the eighth edition, patients <55 years of age with stage II disease had significantly worse DSS (p < 0.001) than patients ≥55 years with stage II disease but appeared to be similar to patients ≥55 years with stage III (p = 0.742) and IV disease (p = 0.566). Patients ≥55 years old with T3a and T3b disease had 10-year DSS of 67% and 92%, respectively (p = 0.390). CONCLUSION: The AJCC eighth edition is similar to the seventh edition in disease-specific survival prediction. Potential modifications that may improve disease-specific survival prediction in future renditions include reconsideration of T3b tumor category and upstaging classification of patients <55 years of age with distant metastases.
引用
- Tam S, Boonsripitayanon M, Amit M, et al. Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions. Thyroid. 2018. PMID: 30141373. doi:10.1089/thy.2017.0572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。